The FDA assessed the security and efficiency of atidarsagene autotemcel depending on information from 37 children who been given atidarsagene autotemcel in two solitary-arm, open-label medical trials and in an expanded entry system.[seven] Little ones who obtained treatment with atidarsagene autotemcel were being as compared to untreated little one